Biopharma industry veteran joins Scorpius’ management staff
DURHAM, N.C., May 07, 2024 (Globe NEWSWIRE) — Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated agreement enhancement and producing organization (CDMO), currently declared the appointment of Shari Udoff-McDonald as VP of Business Enhancement. She delivers a lot more than 25 several years of encounter in biopharma enterprise growth and administration.
Prior to signing up for Scorpius, Ms. Udoff-McDonald expended 17 years at BioReliance Corporation, component of MilliporeSigma. She was most not too long ago Head of Professional, North The us, East with interim oversight of half of the European market. Her position involved professional oversight of biologics, vaccines, cell and gene therapies, ADCs, and mRNA GMP tests solutions for sponsors and CDMOs.
Joe Payne, Scorpius’ President and COO, stated, “Shari has the exceptional combination of experience in the area, at the account-degree, and in management roles. This huge breadth of small business advancement working experience will assistance Scorpius keep on to mature its shopper base. I’m confident that Shari will have an speedy, beneficial effects on our recent and foreseeable future shoppers.”
Ms. Udoff-McDonald will oversee the enterprise development, internet marketing, and proposals teams, which are addressing the potent desire for adaptable mammalian and microbial biomanufacturing products and services. Scorpius’ facility in San Antonio, Texas, has readily available potential for mammalian and microbial courses, which are supported by on-site procedure and analytical growth solutions.
“I’m thrilled to be a part of Scorpius BioManufacturing at this crucial growth stage,” reported Ms. Udoff-McDonald. “Scorpius is committed to remaining a transparent, versatile, and responsive CDMO spouse. I am impressed by their complex and scientific abilities and am even much more impressed by the enthusiasm and enthusiasm exhibited by the crew. I search forward to performing with current and foreseeable future shoppers to convey their huge molecule medicine to current market.”
Ms. Udoff-McDonald and the Scorpius business enterprise growth crew will be at the BIO International Convention in San Diego on June 3-6. To timetable a conference, go to https://www.scorpiusbiologics.com/speak to-us.
About Scorpius Holdings
Scorpius BioManufacturing Inc. is a wholly owned subsidiary of Scorpius Holdings Inc., an built-in agreement progress and producing group (CDMO) targeted on rapidly advancing biologic and mobile remedy applications to the clinic and beyond. Scorpius delivers a wide array of analytical tests, procedure improvement, and manufacturing services to pharmaceutical and biotech corporations at its point out-of-the-artwork facilities in San Antonio, TX. With an expert staff and new, objective-designed U.S. facilities, Scorpius is focused to transparent collaboration and flexible, large-high quality biologics biomanufacturing. For extra info, please go to www.scorpiusbiologics.com.
Forward-Looking Assertion
This release incorporates ahead-on the lookout statements in just the which means of the Non-public Securities Litigation Reform Act of 1995. In some instances, forward-hunting statements can be determined by terminology these as “may well,” “really should,” “probable,” “continue on,” “expects,” “anticipates,” “intends,” “ideas,” “believes,” “estimates,” and very similar expressions, and consist of statements these kinds of as contributions to be manufactured by Shari Udoff-McDonald which includes her enterprise progress practical experience assisting Scorpius continuing to improve its client base and working with recent and upcoming purchasers to bring their large molecule medication to market place. Crucial elements that could lead to real results to differ materially from current expectations include things like, among others, the potential of Shari Udoff-McDonald to make contributions to Scorpius, the Company’s capability to get back compliance with the NYSE American ongoing listing requirements, expand its large molecule biomanufacturing CDMO solutions and go on to develop revenue the Company’s funding desires, its dollars stability being ample to maintain operations and its means to increase capital when wanted, the Company’s capacity to leverage fastened prices and obtain very long-term profitability the Company’s capability to attain regulatory approvals or to comply with ongoing regulatory specifications, regulatory constraints relating to the Company’s potential to successfully boost its solutions and contend as a pure- participate in CDMO, and other components explained in the Company’s most the latest yearly report on Variety 10-K for the year finished December 31, 2023, subsequent quarterly reviews on Type 10-Qs and any other filings the Company can make with the SEC. The information and facts in this presentation is furnished only as of the day introduced, and the Enterprise undertakes no obligation to update any forward-on the lookout statements contained in this presentation on account of new facts, foreseeable future functions, or in any other case, except as essential by regulation.
Media & Trader Relations Call
David Waldman
+1 919 289 4017
[email protected]
